RF | SRF<lc(0.247) | lc≤SRF<0.5 | 0.5≤SRF<hc(0.714) | SRF≥hc | ||||
---|---|---|---|---|---|---|---|---|
 | Benign | Low suspicion | Intermediate suspicion | High suspicion | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 145 | 6 | 91 | 14 | 21 | 37 | 21 | 912 |
 | 96.0% | 4.00% | 86.7% | 13.3% | 36.2% | 63.8% | 2.2% | 97.8% |
LR | SLR<lc(0.470) | lc≤SLR<0.5 | 0.5≤SLR<hc(0.796) | SLR≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 130 | 35 | 5 | 8 | 74 | 165 | 69 | 761 |
 | 78.8% | 21.2% | 38.5% | 61.5% | 31.0% | 69.0% | 8.3% | 91.7% |
SVM | SSVM<lc(0.467) | lc≤SSVM<0.5 | 0.5≤SSVM<hc(0.863) | SSVM≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 122 | 24 | 4 | 2 | 81 | 166 | 68 | 777 |
 | 83.6% | 16.4% | 66.7% | 33.3% | 33.6% | 66.4% | 8.0% | 92.0% |
NET | SNET<lc(0.465) | lc≤SNET<0.5 | 0.5≤SNET<hc(0.840) | SNET≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 135 | 32 | 3 | 3 | 66 | 169 | 74 | 765 |
 | 80.8% | 19.2% | 50.0% | 50.0% | 29.1% | 71.9% | 8.8% | 91.2% |
ELM | SELM<lc(0.409) | lc≤SELM<0.5 | 0.5≤SELM<hc(0.779) | SELM≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 120 | 27 | 0 | 0 | 89 | 182 | 70 | 760 |
 | 81.6% | 18.4% | — | — | 32.8% | 67.2% | 8.4% | 91.6% |
KNN | SKNN<lc(0.466) | lc≤SKNN<0.5 | 0.5≤SKNN<hc(0.833) | SKNN≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 125 | 31 | 0 | 0 | 96 | 247 | 57 | 691 |
 | 80.1% | 19.9% | — | — | 28.0% | 72.0% | 7.6% | 92.4% |
NB | SNB<lc(0.391) | lc≤SNB<0.5 | 0.5≤SNB<hc(0.836) | SNB≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 148 | 72 | 9 | 14 | 27 | 90 | 94 | 793 |
 | 67.3% | 32.7% | 39.1% | 60.9% | 23.1% | 76.9% | 10.6% | 89.4% |
ADAB | SADAB<lc(0.406) | lc≤SADAB<0.5 | 0.5≤SADAB<hc(0.560) | SADAB≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 135 | 9 | 100 | 24 | 15 | 36 | 28 | 900 |
 | 93.8% | 6.2% | 80.6% | 19.4% | 29.4% | 70.6% | 3.0% | 97.0% |
LOG | SLOG<lc(0.498) | lc≤SLOG<0.5 | 0.5≤SLOG<hc(0.802) | SLOG≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 127 | 38 | 0 | 0 | 80 | 167 | 71 | 764 |
 | 77.0% | 23.0% | — | — | 32.4% | 67.6% | 8.5% | 91.5% |
LDA | SLDA<lc(0.464) | lc≤SLDA<0.5 | 0.5≤SLDA<hc(0.879) | SLDA≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 130 | 39 | 3 | 8 | 73 | 172 | 72 | 750 |
 | 76.9% | 23.1% | 27.3% | 72.7% | 29.8% | 70.2% | 8.8% | 91.2% |
Management | After a 6-month | After 3-month | Â | FNA biopsy | ||||
of thyroid | sonographic | sonographic follow-up | FNA biopsy | or surgical | ||||
nodules | follow-up | or FNA biopsy | Â | treatment |